News and Trends 18 Feb 2022 Belgian VC Fund Leads Investment Wave in Japanese Biotech …and metabolic diseases. In 2017, Newton Biocapital launched its first VC fund, Newton Biocapital I (NBC I), worth €114M. The firm established startups including Epics Therapeutics and ChromaCure in Belgium,… February 18, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 28 Sep 2023 Obesity drug success sparks biotech buying spree …acquire Embark Biotech and its lead asset targeting obesity and other cardiometabolic diseases, alongside entering a three-year research and development collaboration to discover and develop novel pharmaceuticals to treat obesity… September 28, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 Gene therapy approval “game changer” in hemophilia B treatment …Hemgenix is worth the asking price of $3.5 million. This is especially the case for rare diseases with small patient pools. “Out of 25,000 male births in the U.S., ‘only’… November 24, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2023 Is Africa ready to become the next big biopharma and vaccine manufacturing destination? …short) are also often more receptive than large multinational corporations to focusing on neglected diseases, especially when those diseases remain endemic in their country or region.” Fortunately, things are starting… October 20, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Jul 2022 Deep phenotyping brings accuracy to precision medicine …not account for the level of complexity that underlies diseases and, as a result, fails to establish the causality of disease, instead focusing on one or few biomarkers that are… July 18, 2022 - 8 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2020 Mogrify Teams Up With Sangamo To Streamline Cell Immunotherapies …Treg cell therapies for inflammatory and autoimmune diseases. Under the terms of the agreement, Mogrify will receive an undisclosed upfront payment from Sangamo and will also be eligible to receive… April 23, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
In Depth 18 May 2020 Will Covid-19 Change the Face of Vaccine Development? …recent outbreaks of diseases such as Ebola, SARS and now Covid-19 have been a wake-up call to both investors and governments about the importance of pandemic preparedness. As of May… May 18, 2020 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2022 Upstream Bio to target asthma as it launches with $200M financing …program UPB-101, a clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. It added the investment will also help build a pipeline of assets to address immune-mediated diseases. The… June 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Replay Bio launches HSV gene therapy company to target retinal eye disease …addressing genetic eye diseases caused by large genes and genomic genes. “This will result in an increased variety of gene therapy options for patients with genetic eye diseases,” Mahajan said…. October 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Collaboration to explore gene therapy products for neurodegenerative disorders Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research… September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 10 Nov 2022 Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures…. November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2019 Swiss Biotech Raises €20M to Develop Decoy Drugs in Autoimmune Disease …highly specific treatment approach is fundamentally new and could potentially enable treatment options for previously incurable diseases.” Healthy nerve cells (left) have support cells wrapped around them to help conduct… March 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email